Top

Published in:

01-08-2010 | Invited Commentary

Concordance of HER2 in primary tumor and leptomeningeal metastases: now what?

Author: Nancy U. Lin

Published in: Breast Cancer Research and Treatment | Issue 1/2010

Excerpt

Breast cancer is the solid tumor most commonly associated with leptomeningeal metastases (LM) [1]. Although the absolute incidence is low, patients with LM often present with debilitating symptoms, including pain, headache, cranial nerve palsies, limb weakness, and alterations in mental status, and therefore the clinical implications are significant [2]. Unfortunately, despite multimodality therapy, the prognosis is generally poor. At present, standard therapies for LM do not take into account tumor subtype, though targeted, subtype-specific therapies are increasingly being employed in the treatment of patients with advanced breast cancer without active CNS involvement. …

Wasserstrom WR, Glass JP, Posner JB (1982) Diagnosis and treatment of leptomeningeal metastases from solid tumors: experience with 90 patients. Cancer 49(4):759–772CrossRefPubMed

Fisher R, DeAngelis LM (2010) Leptomeningeal metastasis. In: Harris JR, Lippman ME, Morrow M, Osborne CK (eds) Disease of the breast, 4th edn. Lippincott Williams & Wilkins, Philadelphia, pp 1000–1007

Fuchs IB, Loebbecke M, Buhler H et al (2002) HER2 in brain metastases: issues of concordance, survival, and treatment. J Clin Oncol 20(19):4130–4133CrossRefPubMed

Johnson ML, Nehhozina T, Conlin AK et al (2008) Clinical and pathologic correlates in breast cancer (BC) brain metastasis (BM): tissue microarray (TMA) studies. J Clin Oncol 26(May 20 suppl):abstract 1039

Gancberg D, Di Leo A, Cardoso F et al (2002) Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites. Ann Oncol 13(7):1036–1043CrossRefPubMed

MacFarlane R, Speers C, Masoudi H, Chia S (2008) Molecular changes in the primary breast cancer versus the relapsed/metastatic lesion from a large population-based database and tissue microarray series. J Clin Oncol 26(May 20 suppl):Abstract 1000

Liedtke C, Broglio K, Moulder S et al (2009) Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer. Ann Oncol 20(12):1953–1958CrossRefPubMed

Wu JM, Fackler MJ, Halushka MK et al (2008) Heterogeneity of breast cancer metastases: comparison of therapeutic target expression and promoter methylation between primary tumors and their multifocal metastases. Clin Cancer Res 14(7):1938–1946CrossRefPubMed

Nam BH, Kim SY, Han HS et al (2008) Breast cancer subtypes and survival in patients with brain metastases. Breast Cancer Res 10(1):R20CrossRefPubMed

10.

Bendell JC, Domchek SM, Burstein HJ et al (2003) Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 97(12):2972–2977CrossRefPubMed

11.

Brufsky AM, Mayer M, Rugo HS et al (2008) RegistHER: patient characteristics and time course of central nervous system metastases in patients with HER2-positive metastatic breast cancer. In: ASCO Breast cancer symposium, 2008, p Abstract 89, Washington, D.C., 2008

12.

Altundag K, Bondy ML, Mirza NQ et al (2007) Clinicopathologic characteristics and prognostic factors in 420 metastatic breast cancer patients with central nervous system metastasis. Cancer 110(12):2640–2647CrossRefPubMed

13.

Lamovec J, Bracko M (1991) Metastatic pattern of infiltrating lobular carcinoma of the breast: an autopsy study. J Surg Oncol 48(1):28–33CrossRefPubMed

14.

Bidard FC, Guilhaume MN, Gauthier H, Cottu PH, Dieras V, Pierga JY (2009) Meningeal carcinomatosis in HER2-overexpressing breast cancers. J Neurooncol 93(2):287–288CrossRefPubMed

15.

Gauthier H, Guilhaume M-N, Bidard FC et al (2009) Meningeal carcinomatosis in patients with breast cancer: clinical features and prognostic factors in 91 patients from a single institution. Cancer Res 69(Suppl):abstract 1090

16.

Lin NU, Claus E, Sohl J, Razzak AR, Arnaout A, Winer EP (2008) Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases. Cancer 113(10):2638–2645CrossRefPubMed

17.

Stemmler HJ, Schmitt M, Harbeck N et al (2006) Application of intrathecal trastuzumab (Herceptintrade mark) for treatment of meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer. Oncol Rep 15(5):1373–1377PubMed

18.

Stemmler HJ, Mengele K, Schmitt M et al (2008) Intrathecal trastuzumab (Herceptin) and methotrexate for meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer: a case report. Anti-cancer drugs 19(8):832–836CrossRefPubMed

19.

Platini C, Long J, Walter S (2006) Meningeal carcinomatosis from breast cancer treated with intrathecal trastuzumab. Lancet Oncol 7(9):778–780CrossRefPubMed

20.

Siderov J (2006) Care with intrathecal trastuzumab. Lancet Oncol 7(11):888CrossRefPubMed

21.

Tham YL, Hinckley L, Teh BS, Elledge R (2006) Long-term clinical response in leptomeningeal metastases from breast cancer treated with capecitabine monotherapy: a case report. Clin Breast Cancer 7(2):164–166CrossRefPubMed

22.

Shigekawa T, Takeuchi H, Misumi M et al (2009) Successful treatment of leptomeningeal metastases from breast cancer using the combination of trastuzumab and capecitabine: a case report. Breast Cancer 16(1):88–92CrossRefPubMed

23.

Lin NU, Dieras V, Paul D et al (2009) Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res 15(4):1452–1459CrossRefPubMed

24.

Boccardo F, Kaufman B, Baselga J et al (2008) Evaluation of lapatinib (Lap) plus capecitabine (Cap) in patients with brain metastses (BM) from HER2 + breast cancer (BC) enrolled in the Lapatinib Expanded Access Program (LEAP) and French Authorisation Temporaire d’Utilisation (ATU). J Clin Oncol 26:abstract 1094

25.

Engelman JA, Zejnullahu K, Mitsudomi T et al (2007) MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316(5827):1039–1043CrossRefPubMed

26.

Ghoussoub RA, Dillon DA, D’Aquila T, Rimm EB, Fearon ER, Rimm DL (1998) Expression of c-met is a strong independent prognostic factor in breast carcinoma. Cancer 82(8):1513–1520CrossRefPubMed

27.

Shattuck DL, Miller JK, Carraway KL III, Sweeney C (2008) Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells. Cancer Res 68(5):1471–1477CrossRefPubMed

Title: Concordance of HER2 in primary tumor and leptomeningeal metastases: now what?
Author: Nancy U. Lin
Publication date: 01-08-2010
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 1/2010
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-009-0720-7

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2010

XRCC2 Arg188His polymorphism is not directly associated with breast cancer risk: evidence from 37,369 subjects

Cyclin D1 is a direct target of JAG1-mediated Notch signaling in breast cancer

Systematic review of aromatase inhibitors in the first-line treatment for hormone sensitive advanced or metastatic breast cancer

Associations between XPD polymorphisms and risk of breast cancer: a meta-analysis

Weekly paclitaxel improved pathologic response of primary chemotherapy compared with standard 3 weeks schedule in primary breast cancer

Treatment of breast cancer through the application of irreversible electroporation using a novel minimally invasive single needle electrode

Keynote webinar | Spotlight on antibody–drug conjugates in cancer